DRUG · Unmapped registry intervention
Rosiglitazone Extended Release 2mg
Find medicine records ·
Find other trials using this name
Clinical trial
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
NCT00348309
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Rosiglitazone Extended Release 8mg
Find medicine records ·
Find other trials using this name
OTHER · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
OTHER · Unmapped registry intervention
Donepezil
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedRosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
Design: INTERVENTIONAL · Status: COMPLETED · Phase: NA
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Alzheimer's Diseaseverified · MONDO: Alzheimer disease
Interventions
Sponsors & collaborators
GlaxoSmithKlinelead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00348309 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.